- Home
- NNY vs FENC Comparison
NNY vs FENC Comparison
Compare NNY & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- FENC
- Stock Information
- Founded
- NNY 1987
- FENC 1996
- Country
- NNY United States
- FENC United States
- Employees
- NNY N/A
- FENC N/A
- Industry
- NNY Investment Managers
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NNY Finance
- FENC Health Care
- Exchange
- NNY Nasdaq
- FENC Nasdaq
- Market Cap
- NNY 156.0M
- FENC 156.9M
- IPO Year
- NNY N/A
- FENC 2001
- Fundamental
- Price
- NNY $8.27
- FENC $5.95
- Analyst Decision
- NNY
- FENC Strong Buy
- Analyst Count
- NNY 0
- FENC 2
- Target Price
- NNY N/A
- FENC $14.00
- AVG Volume (30 Days)
- NNY 50.9K
- FENC 50.4K
- Earning Date
- NNY 01-01-0001
- FENC 05-20-2025
- Dividend Yield
- NNY 4.04%
- FENC N/A
- EPS Growth
- NNY N/A
- FENC N/A
- EPS
- NNY N/A
- FENC N/A
- Revenue
- NNY N/A
- FENC $47,538,000.00
- Revenue This Year
- NNY N/A
- FENC $2.68
- Revenue Next Year
- NNY N/A
- FENC $71.63
- P/E Ratio
- NNY N/A
- FENC N/A
- Revenue Growth
- NNY N/A
- FENC 123.69
- 52 Week Low
- NNY $7.58
- FENC $3.96
- 52 Week High
- NNY $8.87
- FENC $10.07
- Technical
- Relative Strength Index (RSI)
- NNY 57.61
- FENC 51.33
- Support Level
- NNY $8.13
- FENC $5.85
- Resistance Level
- NNY $8.40
- FENC $6.61
- Average True Range (ATR)
- NNY 0.08
- FENC 0.36
- MACD
- NNY 0.03
- FENC 0.06
- Stochastic Oscillator
- NNY 69.05
- FENC 54.20
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing primarily in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.